The Assistance Fund to Provide Financial Assistance to Atypical Hemolytic-Uremic Syndrome Patients.
M2 PHARMA-January 10, 2018-The Assistance Fund to Provide Financial Assistance to Atypical Hemolytic-Uremic Syndrome Patients
(C)2018 M2 COMMUNICATIONS
- Orlando, Florida-based independent charitable patient assistance foundation The Assistance Fund has initiated a program to provide financial support to patients with atypical hemolytic-uremic syndrome, the company said.
The new fund will assist individuals with out-of-pocket medical expenses associated with their condition and treatment, including copayments and coinsurance, health insurance premiums and incidental medical expenses.
People with atypical hemolytic-uremic syndrome experience kidney damage and acute kidney failure that lead to end-stage renal disease in about half of all cases.
The condition can occur at any age and is estimated to affect 1 in 500,000 people per year in the United States.
The Assistance Fund helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles, and other health-related expenses.
It currently manages more than 30 funds, each of which covers the FDA-approved medications that treat a specific disease. Since its founding in 2009, The Assistance Fund has helped more than 43,000 adults and children access the medicines they need to stay healthy or manage a chronic condition.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 10, 2018|
|Previous Article:||ICON Appoints Dr. James Cummings as president of ClinicalRM.|
|Next Article:||ArTara Therapeutics Names Randall Marshall, MD as Chief Medical Officer.|